At Forbion Capital Partners we invest in Life Sciences and Biomedical Technology companies developing world-class drugs and technologies, with a clear focus on product development.
The Forbion team is specialized in the evaluation of late stage preclinical and early stage clinical development programs. We focus on companies that have innovative technologies and drug development programs with unique advantages over current treatments. Furthermore, we invest in medical device companies with a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to market approval.
Our involvement continues beyond the initial investment. We work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of our portfolio company's products and technologies.